Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp Ads (NQ: AMRN )

6.950 USD -0.350 (-4.79%)
Official Closing Price Updated: 7:59 PM EST, Feb 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Amarin Corp Ads

< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference
From GlobeNewswire News Releases
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation
From GlobeNewswire News Releases
Thinking about buying stock in Advanced Micro Devices, Lonestar Resources, Amarin Corp, SmileDirectClub, or Vera Bradley?
InvestorsObserver issues critical PriceWatch Alerts for AMD, LONE, AMRN, SDC, and VRA. 
From PR Newswire
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Societ
From GlobeNewswire News Releases
Thinking about buying stock in Aimmune Therapeutics, FSD Pharma, Amarin Corp, Trevena Inc, or American Airlines?
InvestorsObserver issues critical PriceWatch Alerts for AIMT, HUGE, AMRN, TRVN, and AAL. 
From PR Newswire
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
From GlobeNewswire News Releases
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Editorial Projecting Significant Growth for Global Brain Tumor Therapeutics Sector
From InvestorBrandNetwork
Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Brain Tumor Therapeutics Market Targeted to Reach $3.4 Billion by 2025
Financialnewsmedia.com News Commentary 
From PR Newswire
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiol
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Five Presentations, Including Late-Breaking Science Presentation of Final EVAPORATE Study Results 
From GlobeNewswire News Releases
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and
From GlobeNewswire News Releases
US Stocks That Surged Higher This Week: $AMRN $NAK $AGEN
Tags The Market Signal
From The Market Signal
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
From GlobeNewswire News Releases
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations
From GlobeNewswire News Releases
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summ
From GlobeNewswire News Releases
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020
From GlobeNewswire News Releases
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc.
From GlobeNewswire News Releases
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study
From GlobeNewswire News Releases
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education
Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Reduction Indication 
From GlobeNewswire News Releases
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19
From GlobeNewswire News Releases
VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-I
From GlobeNewswire News Releases
Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations
From GlobeNewswire News Releases
Global Dermatologicals Market Is Expected To Reach $36.2 Billion By 2026
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Dermatologicals Market is Expected to Reach $36.2 Billion by 2026
Financialnewsmedia.com News Commentary 
From PR Newswire
Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update
From GlobeNewswire News Releases
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc. 
From Business Wire News Releases
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation plc. 
From Business Wire News Releases
Amarin Investors Who Lost Money Should Contact Block & Leviton: The Firm Is Investigating Securities Fraud at the Company
From GlobeNewswire News Releases
Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)
From GlobeNewswire News Releases
Amarin Comments on Ruling in VASCEPA® ANDA Litigation
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.